Knockdown of the ERβ expression in triple negative breast cancer cells increased the invasiveness of the cells about three fold77, while ERβ agonists had the opposite effect78, raising the possibility of their role in the treatment of these cancers. The gene discussed is ESR2; the disease is cancer.